Read by QxMD icon Read

Adult Growth Hormone Deficiency

Cesar Luiz Boguszewski, Margaret Cristina da Silva Boguszewski
Several components of the GH axis are involved in tumor progression and GH-induced intracellular signaling has been strongly associated with breast cancer susceptibility in genome-wide association studies. In the general population, high IGF-I levels and low IGFBP-3 levels within the normal range are associated with the development of common malignancies, and components of the GH-IGF signaling system exhibit correlations with clinical, histopathological and therapeutic parameters in cancer patients. Despite promising findings in preclinical studies, anti-cancer therapies targeting the GH-IGF signaling system have led to disappointing results in clinical trials...
November 30, 2018: Endocrine Reviews
Hongbo Yang, Kemin Yan, Qi Zhang, Lin Jie Wang, Feng Ying Gong, Hui Juan Zhu, Hui Pan
CONTEXT: Adult growth hormone deficiency (AGHD) is characterized by low bone density and increased risk of fracture. Bone microarchitecture is insufficiently evaluated in patients with childhood-onset AGHD (CO AGHD). OBJECTIVE: To assess volumetric bone density (vBMD) and bone microarchitecture in CO AGHD in early adulthood after cessation of recombinant growth hormone (rhGH) treatment. DESIGN AND SUBJECTS: Case-control study in a major academic medical center in Beijing, including twenty young male adults with CO AGHD and thirty age- and weight-matched non-athletic healthy men...
November 1, 2018: European Journal of Endocrinology
Jane Loftus, Cecilia Camacho-Hubner, Judith Hey-Hadavi, Kelly Goodrich
BACKGROUND: Quality of life (QoL) and health economic data are becoming increasingly important factors in healthcare decision-making. While there is a wealth of information establishing the benefit of growth hormone (GH) replacement therapy on adults with growth hormone deficiency (aGHD), recent reviews on the QoL and health economic impact of aGHD and the effect of treatment on these factors is limited. OBJECTIVE: The aim of this article is to summarise the impact of early and sustained treatment on the QoL and economic burden of aGHD by conducting a targeted literature review...
November 9, 2018: Current Medical Research and Opinion
Ammon Handisurya, Tamara Rumpold, Carola Caucig-Lütgendorf, Birgit Flechl, Matthias Preusser, Aysegül Ilhan-Mutlu, Karin Dieckmann, Georg Widhalm, Anna Grisold, Adelheid Wöhrer, Johannes Hainfellner, Robin Ristl, Christine Kurz, Christine Marosi, Alois Gessl, Marco Hassler
BACKGROUND: So far, the development and course of therapy-induced deficiencies in hypothalamic-pituitary hormones in adult patients with malignant gliomas has not received much attention. However, such deficiencies may impact patient's quality of life substantially. METHODS: In this monocentric longitudinal trial, we examined hormonal levels of TSH, T3, T4, fT3, fT4, FSH, LH, testosterone, estradiol and prolactin in patients with malignant high grade gliomas before the start of radiochemotherapy (RCT), at the end of RCT and then every three months for newly diagnosed patients and every six months in patients diagnosed more than two years before study inclusion...
October 30, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Jakub Mesinovic, Aya Mousa, Kirsty Wilson, Robert Scragg, Magdalena Plebanski, Maximilian de Courten, David Scott, Negar Naderpoor, Barbora de Courten
This randomised placebo-controlled trial aimed to determine the effect of 16-weeks cholecalciferol supplementation on calcium-phosphate homeostasis and bone mineral density (BMD) in overweight and obese adults. Fifty-four vitamin D-deficient (25OHD<50 nmol/L), overweight and obese adults (mean age 32 ± 8.5 years) were included in the trial. Participants were randomly assigned to receive either a bolus oral dose of 100,000 IU cholecalciferol followed by 4000 IU cholecalciferol/d or a matching placebo for 16 weeks...
October 24, 2018: Journal of Steroid Biochemistry and Molecular Biology
Rohan K Henry
In addition to its growth promoting role, growth hormone (GH) has a significant effect on intermediary metabolism in the well state. Despite the latter fact, pediatric practitioners are usually focused on the growth promoting aspects of GH as opposed to those metabolic. In recent years various animal and human studies (in adults mainly) and clinical reports in children have repeatedly shown the association of GH deficiency (GHD) and fatty liver disease. Based on this well-identified association, despite a lack of studies involving children, it behooves the pediatric clinician to ensure that not only patients with GHD are appropriately treated but also that adolescents even beyond the period of linear growth should be appropriately transitioned to adult GH therapy should this be appropriate...
October 20, 2018: Metabolic Syndrome and related Disorders
Ewelina Witkowska-Sędek, Małgorzata Rumińska, Anna Majcher, Beata Pyrżak
Gender seems to be an important factor influencing the response to recombinant human growth hormone (rhGH) therapy in GH-deficient adolescents and adults. The results of studies evaluating gender-specific response to rhGH therapy in prepubertal GH-deficient children are divergent. The aim of this study was to determine the effect of gender on the growth and insulin-like growth factor-1 (IGF-1) responses in 75 prepubertal GH-deficient children during the first 2 years of rhGH therapy. There were no baseline gender differences in age, bone age, anthropometrical parameters, and IGF-1 SDS for bone age...
October 19, 2018: Advances in Experimental Medicine and Biology
Merlin G Butler, Waheeda A Hossain, Robert Tessman, Partha C Krishnamurthy
Prader-Willi syndrome (PWS) is a complex multisystem disorder because of errors in genomic imprinting with severe hypotonia, decreased muscle mass, poor suckling, feeding problems and failure to thrive during infancy, growth and other hormone deficiency, childhood-onset hyperphagia, and subsequent obesity. Decreased energy expenditure in PWS is thought to contribute to reduced muscle mass and physical activity but may also relate to cellular metabolism and disturbances in mitochondrial function. We established fibroblast cell lines from six children and adults with PWS and six healthy controls for mitochondrial assays...
October 5, 2018: American Journal of Medical Genetics. Part A
Alana L Andrade-Guimarães, Manuel H Aguiar-Oliveira, Roberto Salvatori, Vitor O Carvalho, Fabiano Alvim-Pereira, Carlos R Araújo Daniel, Giulliani A Moreira Brasileiro, Ananda A Santana-Ribeiro, Hugo A Santos-Carvalho, Carla R P Oliveira, Edgar R Vieira, Miburge B Gois-Junior
PURPOSE: While growth hormone (GH) and the insulin-like growth factor type I (IGF-I) are known to exert synergistic actions on muscle anabolism, the consequences of prolonged GH deficiency (GHD) on muscle function have not been well defined. We have previously described a large cohort of subjects with isolated GHD (IGHD) caused by a mutation in the GH-releasing hormone receptor gene, with low serum levels of GH and IGF-I. The aim of this study was to assess muscular function in these IGHD subjects...
September 24, 2018: Endocrine
Roland Pfäffle, Christof Land, Eckhard Schönau, Paul-Martin Holterhus, Judith L Ross, Carolina Piras de Oliveira, Christopher J Child, Imane Benabbad, Nan Jia, Heike Jung, Werner F Blum
BACKGROUND/AIMS: To describe characteristics, auxological outcomes and safety in paediatric patients with growth disorders treated with growth hormone (GH), for cohorts from the USA, Germany and France enrolled in GeNeSIS, a post-authorisation surveillance programme. METHODS: Diagnosis and biochemical measurement data were based on reporting from, and GH treatment was initiated at the discretion of, treating physicians. Auxological outcomes during the first 4 years of GH treatment and at near-adult height (NAH) were analysed...
2018: Hormone Research in Pædiatrics
Umberto Basile, Carmine Bruno, Cecilia Napodano, Edoardo Vergani, Krizia Pocino, Alessandro Brunetti, Francesca Gulli, Stefano Angelo Santini, Antonio Mancini
Biological functions of immunoglobulin-free light chains (FLCs), other than in chronic inflammatory diseases, are still poorly defined; the field of insulin resistance (IR) has not been investigated, despite the strict relationships with oxidative stress (OS) and inflammation. Therefore, we evaluated FLCs levels and their relationships with metabolic parameters in adult growth hormone deficiency (GHD) and metabolic syndrome (MetS), both characterized by IR. One hundred subjects were enrolled: group A, patients with GHD [n =31, 24-69 years, mean ± SEM body mass index (BMI) 26...
September 2018: BioFactors
Shahnaz A Mir, Tabinda Shah, Hardeep Singh, Iram Shabir, Bashir A Laway
Background: Sheehan syndrome (SS) refers to the occurrence of hypopituitarism after parturition. Hypopituitary adults with growth hormone (GH) deficiency have abnormal body composition with increased fat mass. As leptin is secreted almost exclusively by fat cells and the circulating leptin level is proportional to total fat mass, it is expected that abnormal elevations of leptin concentrations are found in GH deficient hypopituitary patients. The present study was undertaken to evaluate the anthropometric, lipid and leptin levels in patients with SS...
July 2018: Indian Journal of Endocrinology and Metabolism
Wendy Lipworth, Geoffrey Ambler, Morton G Burt, Jan Fairchild, Warrick J Inder, George Werther, Ken Ho
Growth hormone (GH) replacement therapy was recently recommended by the Pharmaceutical Benefits Advisory Committee (PBAC) for listing on the Pharmaceutical Benefits Scheme for adults with severe GH deficiency and impaired quality of life. This approval was significant for two reasons. First, the application was initiated and coordinated by a health professional working group, who prepared a 'public interest' submission to PBAC. Second, it resulted in a recommendation to subsidise therapy for a rare disease after two prior rejections on the basis of uncertainty about efficacy and cost effectiveness...
August 2018: Internal Medicine Journal
Kensaku Fukunaga, Hitomi Imachi, Jingya Lyu, Tao Dong, Seisuke Sato, Tomohiro Ibata, Toshihiro Kobayashi, Takuo Yoshimoto, Kazuko Yonezaki, Toru Matsunaga, Koji Murao
Recently, several clinical studies have suggested that adult growth hormone deficiency that also has low concentration of IGF1 is associated with an increased prevalence of fatty liver (FL). ABCA1 is a pivotal regulator of lipid efflux from cells to apolipoproteins and play an important role on formation of FL. In this study, we determined the effects of IGF1 on ABCA1 expression in GH deficient mice to clarify its effects on FL. Western blotting, real-time PCR and a luciferase assay were employed to examine the effect of IGF1...
August 21, 2018: American Journal of Physiology. Endocrinology and Metabolism
Ralph E Vatner, Andrzej Niemierko, Madhusmita Misra, Elizabeth A Weyman, Claire P Goebel, David H Ebb, Robin M Jones, Mary S Huang, Anita Mahajan, David R Grosshans, Arnold C Paulino, Takara Stanley, Shannon M MacDonald, Nancy J Tarbell, Torunn I Yock
PURPOSE: There are sparse data defining the dose response of radiation therapy (RT) to the hypothalamus and pituitary in pediatric and young adult patients with brain tumors. We examined the correlation between RT dose to these structures and development of endocrine dysfunction in this population. MATERIALS AND METHODS: Dosimetric and clinical data were collected from children and young adults (< 26 years of age) with brain tumors treated with proton RT on three prospective studies (2003 to 2016)...
October 1, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Andrzej Lewiński, Joanna Smyczyńska, Renata Stawerska, Maciej Hilczer, Magdalena Stasiak, Tomasz Bednarczuk, Marek Bolanowski, Roman Junik, Marek Ruchała, Anhelli Syrenicz, Mieczysław Walczak, Wojciech Zgliczyński, Małgorzata Karbownik-Lewińska
Growth hormone (GH) has been used in the treatment of short stature in children with GH deficiency (GHD) for 60 years, and for about 30 years also in the treatment of adults with GHD, in whom such treatment is carried out due to metabolic indications. In Poland, GH treatment is reimbursed only in children with GHD, while so far it has not been refunded in adults with GHD. There are two groups of adults (or adolescents after growth completion) with GHD, who require GH therapy: patients with GHD that occurred in childhood (childhood-onset GHD - CO-GHD) and patients with GHD acquired in adulthood (adulthood-onset GHD - AO-GHD)...
August 17, 2018: Endokrynologia Polska
Nadia Mohamad Amer, Marilza J Modesto, Cláudia Duarte Dos Santos, Oscar Erichsen, Luis P G Mascarenhas, Suzana Nesi-França, Rosana Marques-Pereira, Luiz De Lacerda
Background During the transition phase (TP), patients with growth hormone deficiency (GHD) exhibit decreased muscle strength. Studies assessing the effects of resistance exercise alone on muscle strength in these individuals are scarce. The objective of this study was to evaluate the effects of a program of resistance exercise (PRE) on parameters of muscle strength in subjects in the TP and with childhood-onset GHD treated with recombinant GH (rGH). Methods Sixteen male patients were enrolled and divided into two groups: GHD (n=9) and GH sufficiency (GHS, n=7)...
August 28, 2018: Journal of Pediatric Endocrinology & Metabolism: JPEM
Elizabeth Culpin, Matthew Crank, Mark Igra, Daniel J A Connolly, Paul Dimitri, Showkat Mirza, Saurabh Sinha
OBJECTIVES: To evaluate clinical presentations, diagnosis and management of paediatric patients presenting with pituitary apoplexy. METHODS: A retrospective case series describing a cohort of paediatric patients presenting with this condition from 2010-2016 to a tertiary referral children's hospital in the United Kingdom. RESULTS: Pituitary apoplexy is a rare condition that seems to have a higher relative incidence in children than adults...
October 2018: Pituitary
Stan R Ursem, Marc G Vervloet, Rahel M Büttler, Mariëtte T Ackermans, Mirjam M Oosterwerff, Elisabeth M V Eekhoff, Paul Lips, Mireille J Serlie, Susanne E la Fleur, Annemieke C Heijboer
AIMS: Different studies point to a link between glucose metabolism and Fibroblast Growth Factor 23 (FGF23), an osteocyte-derived phosphaturic hormone. We aimed to investigate in humans the effect of (I) a glucose load and (II) a hyperinsulinemic-euglycemic clamp on FGF23 concentrations and conversely (III) the effect of a diet-induced increase in FGF23 concentration on glucose and insulin concentrations. METHODS: Plasma cFGF23 concentrations were measured during: I...
September 2018: Journal of Diabetes and its Complications
Kerstin Gutefeldt, Christina A Hedman, Ingrid S M Thyberg, Margareta Bachrach-Lindström, Anna Spångeus, Hans J Arnqvist
CONTEXT: In type 1 diabetes (T1D), dysregulation of the GH-IGF-1 axis has been reported. Whether this is related to upper extremity impairments (UEI) is unknown. OBJECTIVE: Examine differences in GH-IGF-1 axis between T1D on subcutaneous insulin treatment and matched controls without diabetes and possible associations between GH-IGF-1 axis and UEI. DESIGN: Cross-sectional population-based study. Patients with T1D, onset <35 years, duration ≥ 20 years, <67 years old and controls were invited to answer questionnaires and take blood samples...
July 10, 2018: Clinical Endocrinology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"